Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
AZD1775
Description:
An anticancer drug, also called adavosertib, that inhibits the WEE1 kinase in cancer research and treatment.
Related topics:
PARP inhibition in cancer therapy (16%),
Cancer-related Molecular Pathways (10%)
Wikidata ID:
wiki/Q27074716
OpenAlex ID:
keywords/azd1775
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies
2016
·
Jennifer O'Neil
, Yair Benita
, et al.
·
Molecular Cancer Therapeutics
·
448
Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
2016
·
Suzanne Leijen
, Robin M.J.M. van Geel
, et al.
·
Journal of Clinical Oncology
·
357
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
2015
·
Sophia X. Pfister
, Enni Markkanen
, et al.
·
Cancer Cell
·
341
Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
2015
·
Khanh Do
, Deborah Wilsker
, et al.
·
Journal of Clinical Oncology
·
341
Orthotopic patient-derived xenografts of paediatric solid tumours
2017
·
Elizabeth Stewart
, Sara M. Federico
, et al.
·
Nature
·
312
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors
2016
·
Suzanne Leijen
, Robin M.J.M. van Geel
, et al.
·
Journal of Clinical Oncology
·
282
Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
2019
·
Kyle C. Cuneo
, Meredith A. Morgan
, et al.
·
Journal of Clinical Oncology
·
210
PDF
Molecular Pathways: Targeting the Protein Kinase Wee1 in Cancer
2017
·
Jill J.J. Geenen
, Jan H.M. Schellens
·
Clinical Cancer Research
·
167
PDF
Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
2014
·
David Karnak
, Carl G. Engelke
, et al.
·
Clinical Cancer Research
·
163
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer
2018
·
Alice Lallo
, Kristopher K. Frese
, et al.
·
Clinical Cancer Research
·
161
PDF
WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC
2022
·
Hirokazu Taniguchi
, Rebecca Caeser
, et al.
·
Cell Reports
·
146
PDF
Targeting AXL and mTOR Pathway Overcomes Primary and Acquired Resistance to WEE1 Inhibition in Small-Cell Lung Cancer
2017
·
Triparna Sen
, Pan Tong
, et al.
·
Clinical Cancer Research
·
143
PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
2017
·
Leslie A. Parsels
, David Karnak
, et al.
·
Molecular Cancer Research
·
142
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer
2020
·
Amit M. Oza
, Maria Estevez-Diz
, et al.
·
Clinical Cancer Research
·
139
Inhibition of WEE1 Is Effective in TP53 - and RAS -Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring
2021
·
Jenny F. Seligmann
, David J. Fisher
, et al.
·
Journal of Clinical Oncology
·
128
PDF
Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition
2018
·
Xian Chen
, Kwang-Huei Low
, et al.
·
Clinical Cancer Research
·
123
PDF
A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma
2018
·
Eduardo Méndez
, Cristina P. Rodriguez
, et al.
·
Clinical Cancer Research
·
115
Harnessing machine learning to find synergistic combinations for FDA-approved cancer drugs
2024
·
Tarek Abd El-Hafeez
, Mahmoud Y. Shams
, et al.
·
Scientific Reports
·
114
PDF
Development and Characterization of a Wee1 Kinase Degrader
2019
·
Zhengnian Li
, Benika J. Pinch
, et al.
·
Cell chemical biology
·
111
PDF
WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
2019
·
Tatiana N. Moiseeva
, Chenao Qian
, et al.
·
Proceedings of the National Academy of Sciences
·
104
PDF
Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer
2018
·
Juan Jin
, Hehui Fang
, et al.
·
Neoplasia
·
101
PDF
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair
2015
·
Tasneem Kausar
, Jason S. Schreiber
, et al.
·
Neoplasia
·
96
PDF
Insights into pediatric rhabdomyosarcoma research: Challenges and goals
2019
·
Marielle E. Yohe
, Christine M. Heske
, et al.
·
Pediatric Blood & Cancer
·
90
Phase 0 Trial of AZD1775 in First-Recurrence Glioblastoma Patients
2018
·
Nader Sanai
, Jing Li
, et al.
·
Clinical Cancer Research
·
89
A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations
2014
·
L Zhou
, Y Zhang
, et al.
·
Leukemia
·
89
Show more works
View as search
Works count:
516
Citation count:
8,677
Year
Topic
Type